Evaluation of a Polyherbal Formulation on the Management of Migraine Headaches due to Functional Dyspepsia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial
- PMID: 36510578
- PMCID: PMC9741544
- DOI: 10.1155/2022/9872933
Evaluation of a Polyherbal Formulation on the Management of Migraine Headaches due to Functional Dyspepsia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial
Abstract
A holistic concept based on traditional Persian medicine (TPM) describes a headache with a gastrointestinal (GI) origin (gastric-headache). Although the neurological manifestations of this headache are similar to those of other headaches, its etiology is different. Considering its simultaneous effects on the brain and GI system, a formulation was designed based on this concept. This study aimed to determine the safety and efficacy of the designed formulation on migraine headache (MH) associated with functional dyspepsia (FD). A total of 75 diagnosed cases of MH patients with concurrent FD were randomly divided equally into 3 groups: (i) the polyherbal formulation, sodium valproate (VPA), and amitriptyline group, (ii) VPA, amitriptyline, and polyherbal formulation placebo group, and (iii) the polyherbal formulation and VPA placebo group. The primary outcomes, including frequency, duration, and severity of MH attacks, were measured at baseline and weeks 4, 8, and 12. However, secondary outcomes, including the Headache Impact Test 6 (HIT-6) Questionnaire and Parkman's score, were evaluated at baseline and end of treatment. The frequency, duration, and severity of migraine (P < 0.001 for all cases), HIT-6 (P < 0.001 for all cases), and FD (P < 0.001 for all cases) scores at the end of treatment showed a significant decrease in the 3 groups compared to the baseline. However, the differences in those variables between the 3 groups were not significant at the end of the study. The polyherbal formulation alone may improve the symptoms of migraine patients and other groups. This effect could be due to improving digestion and FD in migraine patients.
Copyright © 2022 Majid Anushiravani et al.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9741544/bin/ECAM2022-9872933.001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9741544/bin/ECAM2022-9872933.002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9741544/bin/ECAM2022-9872933.003.gif)
Similar articles
-
Effect of a traditional syrup from Citrus medica L. fruit juice on migraine headache: A randomized double blind placebo controlled clinical trial.J Ethnopharmacol. 2016 Feb 17;179:170-6. doi: 10.1016/j.jep.2015.12.040. Epub 2015 Dec 22. J Ethnopharmacol. 2016. PMID: 26721220 Clinical Trial.
-
Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial.J Headache Pain. 2021 Apr 7;22(1):21. doi: 10.1186/s10194-021-01234-6. J Headache Pain. 2021. PMID: 33827421 Free PMC article. Clinical Trial.
-
Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.Headache. 2008 Jun;48(6):900-13. doi: 10.1111/j.1526-4610.2007.00953.x. Epub 2007 Nov 28. Headache. 2008. PMID: 18047501 Clinical Trial.
-
Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults.Cochrane Database Syst Rev. 2013 Jun 24;2013(6):CD010608. doi: 10.1002/14651858.CD010608. Cochrane Database Syst Rev. 2013. PMID: 23797674 Free PMC article. Review.
-
A link between gastrointestinal disorders and migraine: Insights into the gut-brain connection.Headache. 2021 Apr;61(4):576-589. doi: 10.1111/head.14099. Epub 2021 Apr 1. Headache. 2021. PMID: 33793965 Free PMC article. Review.
References
-
- Headache S. Classification committee of the international headache, the international classification of headache disorders, 3rd edition (beta version) Cephalalgia: An International Journal of Headache . 2013;33(9):629–808. - PubMed
-
- Arulmozhi D., Veeranjaneyulu A., Bodhankar S. Migraine: current concepts and emerging therapies. Vascular Pharmacology . 2005;43(3):176–187. - PubMed
-
- Mohammadi Vosough E., Baradaran Rahimi V., Masoud S. A., et al. Evaluation of protective effects of non-selective cannabinoid receptor agonist WIN 55, 212-2 against the nitroglycerine-induced acute and chronic animal models of migraine: a mechanistic study. Life Sciences . 2019;232 doi: 10.1016/j.lfs.2019.116670.116670 - DOI - PubMed
-
- Leonardi M., Steiner T. J., Scher A. T., Lipton R. B. The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF) The Journal of Headache and Pain . 2005;6(6):429–440. doi: 10.1007/s10194-005-0252-4. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources